Results 61 to 70 of about 206,966 (309)

Gene and protein expression of glucose transporter 1 and glucose transporter 3 in human laryngeal cancer—the relationship with regulatory hypoxia-inducible factor-1α expression, tumor invasiveness, and patient prognosis [PDF]

open access: yes, 2014
Increased glucose uptake mediated by glucose transporters and reliance on glycolysis are common features of malignant cells. Hypoxia-inducible factor-1α supports the adaptation of hypoxic cells by inducing genes related to glucose metabolism.
Anna Krześlak   +51 more
core   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

open access: yesAdvanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong   +5 more
wiley   +1 more source

Synergy of electrochemotherapy and immunotherapy in the treatment of skin squamous cell carcinoma of the head and neck

open access: yesOral and Maxillofacial Surgery Cases, 2023
Treatment of advanced-stage head and neck cutaneous squamous cell carcinoma is a challenge for maxillofacial surgeons, oncologists, and radiotherapists.
Ida Barca   +3 more
doaj   +1 more source

Survival Prediction in Head and Neck Cancer: Impact of Tumor and Patient Specific Characteristics [PDF]

open access: yes, 2012
Head and neck cancer accounts for almost 5% of all malignant tumors in the Netherlands. The most up‐todate Dutch Cancer Registry (NCR) database from 2009 reported 2878 new patients with an invasive carcinoma of the lip, oral cavity, pharynx and ...
Datema, F.R. (Frank)
core  

Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas [PDF]

open access: yes, 2018
This integrated, multiplatform PanCancer Atlas study co-mapped and identified distinguishing molecular features of squamous cell carcinomas (SCCs) from five sites associated with ...
Abdel-Rahman, Mohamed H.   +784 more
core   +2 more sources

β‐Adrenergic Signaling Promotes Anti‐Tumor Immunity in TP53‐mutant Oral Squamous Cell Carcinoma

open access: yesAdvanced Science, EarlyView.
β‐adrenergic stimulation enhances anti‐tumor immunity in TP53‐deficient oral squamous cell carcinoma by inducing tumor‐derived secretion of CXCL10, which attracts and activates cytotoxic CD8+ T cells. The findings demonstrate that β‐adrenergic signaling alters tumor–immune interactions via CXCL10‐mediated paracrine activation, revealing a neuro‐immune ...
Frederico O. Gleber‐Netto   +20 more
wiley   +1 more source

Fibroblast growth factor receptor 4 single nucleotide polymorphism Gly388Arg in head and neck carcinomas [PDF]

open access: yes, 2019
BACKGROUND Head and neck squamous cell carcinoma (HNSCC) is considered to be a progressive disease resulting from alterations in multiple genes regulating cell proliferation and differentiation like receptor tyrosine kinases (RTKs) and members of the ...
Bergmann, C.   +5 more
core   +2 more sources

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

open access: yesAdvanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu   +11 more
wiley   +1 more source

Basaloid squamous cell carcinoma of the head and neck: Our experience

open access: yesJournal of Head & Neck Physicians and Surgeons, 2020
Basaloid squamous cell carcinoma (BSCC) of the head and neck is a distinctive variant of squamous cell carcinoma known for its basaloid appearance and aggressive behavior.
Jaimanti Bakshi   +5 more
doaj   +1 more source

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. [PDF]

open access: yes, 2016
Purpose Treatment with pembrolizumab, an anti-programmed death-1 antibody, at 10 mg/kg administered once every 2 weeks, displayed durable antitumor activity in programmed death-ligand 1 (PD-L1) -positive recurrent and/or metastatic (R/M) head and neck ...
Berger, Raanan   +21 more
core   +2 more sources

Home - About - Disclaimer - Privacy